Delaware Court Consolidates, Postpones Trial In Adderall XR Patent Challenge

Law360, New York (April 15, 2005, 12:00 AM EDT) -- A Delaware federal court has postponed the trial in Impax Laboratories, Inc.’s patent challenge against Shire Pharmaceuticals Group’s best-selling attention-deficit-disorder treatment Adderall XR until February 2006.

Shire has two pending suits against Impax based on the generics maker’s plans to make 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg generic versions of Adderall XR.

Impax sent Shire two separate notices that it would be challenging the validity of the main ingredients in the drug, prompting two separate lawsuits for different dosages....
To view the full article, register now.